XIANNUOXIN is the first 3CL-targeting anti-COVID-19 innovative drug with independent intellectual property rights in China, which inhibits the 3CL protease necessary for SARS-CoV-2 viral replication, making the virus lose its ability to infect normal cells and spread. 

It is effective for all known COVID-19 mutants, with good overall safety.